ABC | Volume 114, Nº5, May 2020

Review Article Askin et al. COVID-19 and cardiovascular diseases Arq Bras Cardiol. 2020; 114(5):817-822 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 Feb 19. [Epub ahead of print] 2. Chan JW, Ng CK, Chan YH, Mok TYW, Lee S, Chu SY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686-9. 3. Badawi A, Ryoo SG. Prevalence of comorbidades in the Middle East respiratory syndrome coronavírus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:129-33. 4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2. 5. ZhangT,WuQ,ZhangZ.ProbablepangolinoriginofSARS-CoV-2associated with the COVID-19 outbreak. Curr Biol. 2020;30(8):1578. 6. HoffmannM, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ECA2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80. 7. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, ZuoW. Single-cell RNA expression profiling of ECA2, the putative receptor of Wuhan 2019-nCov. bioRxiv. 2020 Jan 26. 8. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ECA2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:256294. 9. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ECA2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-90. 10. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801-9. 11. Badawi A, Ryoo SG. Prevalence of comorbidades in the Middle East respiratory syndrome coronavírus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:129-33. 12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpacientes with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. 13. WangD,HuB,HuC,ZhuF,LiuX,Zhang J,etal.Clinicalcharacteristicsof138 hospitalized pacientes with 2019 novel coronavírus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. 14. GuanWJ, Ni ZY, Hu Y, LiangWH, OuCQ, He JX, et al. Clinical characteristics of coronavírus disease 2019 in China. New Eng J Med. 2020 Feb 28. [Epub ahead of print]. 15. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. 16. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidades in the novel Wuhan coronavírus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020 Mar 12:pii:S1201-9712(20)30136-3. 17. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. OurWorld In Data [Internet]. Statistics and research: coronavírus disease (COVID-19); 2020. [citado 22 mar 2020]. Disponível em: https://ourworldindata. org/coronavirus. 18. Hu H, Ma F, Wei X, Fang Y. Coronavírus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020 Mar 16:pii:ehaa190. [Epub ahead of print]. 19. Zeng JH, Liu YX, Yuan J,Wang FX,WuWB, Li JX, et al. First case of COVID-19 infectionwith fulminant myocarditis complication: case report and insights. Preprints. 2020;2020030180. 20. Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Pacientes with Confirmed Coronavírus Disease (COVID-19). Revised March 7th; 2020. [citado 22 mar 2020]. Disponível em: https://www.cdc.gov/coronavírus/2019-ncov/hcp/clinical-guidance- management pacientes.html. 21. WorldHealthOrganization.Clinicalmanagementofsevereacuterespiratory infection (SARI) when COVID-19 disease is suspected; 2020. [citado 13 mar 2020]. Disponível em: https://www.who.int/publications-detail/ clinical-management-of-severe-acute respiratoryinfection-when-novel- coronavírus-(ncov)-infection-is-suspected. 22. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS- coronavírus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-25. 23. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801-9. 24. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartana augments renal ECA2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015;19(8):1965-74. 25. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace. 2017;19(8):1280-7. 26. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin‑converting enzyme2protectsfromsevereacutelungfailure.Nature.2005;436(7047):112-6. 27. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavírus-induced lung injury. Nat Med. 2005;11(8):875-9. 28. ClinicalTrials.gov. Losartana for Pacientes With COVID19 Not Requiring Hospitalization. Identifier: NCT04311177; 2020. [citado 17 mar 2020]. Disponível em: https://clinicaltrials.gov/ct2/show/NCT04311177. 29. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020 Mar 21. [Epub ahead of print]. 30. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by2019-nCoV.ZhonghuaXinXueGuanBingZaZhi.2020Mar2;48(0):E004. 31. Si Y, Sun XF, Zhong M, Yue JN, FuWG. Countermeasures and treatment for aortic acute syndrome with 2019 coronavirus disease. ZhonghuaWai Ke Za Zhi 2020;58(3):178-82. 32. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477. 33. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6. 34. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2007. 35. KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL; 2013. 36. DeCarolis DD,Westanmo AD, Chen YC, Boese AL,Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother. 2016;50(11):909-17. 37. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838-46. 38. MueckW, KubitzaD, BeckaM. Co-administration of rivaroxabanwith drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66. References 821